InterMune, Inc. has discontinued the Phase III INSPIRE trial evaluating Actimmune in patients with idiopathic pulmonary fibrosis (IPF) based on the recommendation of an independent data monitoring committee (DMC). Interim analysis included a total of 115 deaths and the DMC found the overall survival result crossed a predefined stopping point for lack of benefit of Actimmune relative to placebo. There wasn’t a statistically significant difference between treatment groups in overall mortalit...